Status:

COMPLETED

Juice Plus+OMEGA Study

Lead Sponsor:

Green Beat

Collaborating Sponsors:

Medical University of Graz

Conditions:

Healthy

Eligibility:

All Genders

20-65 years

Phase:

NA

Brief Summary

In this randomized, controlled clinical study firstly the bioavailability of fatty acids and micronutrients of JP+® Omega Blend will be analysed. Secondly, the effect of the constituents contained in ...

Detailed Description

In this randomized, controlled clinical study firstly the bioavailability of fatty acids and micronutrients of JP+Omega Blend will be analysed. Secondly, the effect of the constituents contained in th...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • 80 healthy men and women, 20-65 years
  • suboptimal serum lipid values without medication
  • triglycerides \>140 mg/dl
  • HDL Chol \< 45 (m) or \< 50 mg/dl (w)
  • Non smokers
  • BMI \>20 and \<35 kg/m2
  • ω-3-fatty acid index (ω-3 index): rank 21 - 100 of the ranking or ω-3 index \< 8%
  • normal nutrition (omnivore diet)
  • adherence to the 4-week long wash-out period
  • Exclusion criteria:
  • all people not meeting the inclusion criterions
  • hypertension (systolic blood pressure \> 160mmHg, diastolic blood pressure \>100 mmHg)
  • Specific diets and nutritional habits (vegan, vegetarian, paleo, low-carb pregnancy)
  • aversion to stop the intake of nutritional supplements and food, that could interfere with the study outcome
  • over-consumption of fish (\> 1 portion/week)
  • linseed and walnut oil, whole linseeds and walnuts (\>1 portion (25g)/day)
  • with omega-3 fatty acids enriched "functional food
  • intake of lipid-lowering, anti-inflammatory, blood pressure lowering medication and anticoagulants
  • clinically relevant infectious disease
  • acute and chronic inflammatory disease
  • Diabetes mellitus type I and type II
  • supplementation of antioxidants in all variations, omega-3 fatty acids, plant extracts/concentrates

Exclusion

    Key Trial Info

    Start Date :

    September 1 2017

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    February 3 2020

    Estimated Enrollment :

    72 Patients enrolled

    Trial Details

    Trial ID

    NCT03348553

    Start Date

    September 1 2017

    End Date

    February 3 2020

    Last Update

    August 6 2020

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Institute of Pathophysiology and Immunology

    Graz, Styria, Austria, 8010

    2

    Green Beat

    Graz, Austria, 8042